News for Sanofi (SNY)

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adu

Sanofi (SNY) stock slips as the company's asthma therapy amlitelimab fails in a Phase 2 trial, despite its plans to evaluate it in a Phase 3 trial. Read more here.

**media[595109]**

**media[589564]**

**media[584597]**

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

**media[579891]**

**media[579109]**

**media[576714]**

Sanofi's tolebrutinib gains FDA priority review for multiple sclerosis treatment. Read more here,

**media[574306]**

NCAA March Madness: Watch DraftKings, FanDuel, Robinhood, and Grand Canyon. CoreWeave seeks shares ranging from $47 to $55 in IPO:report. Sanofi strikes autoimmune drug deal for up to $1.9B.

Sanofi (SNY) to acquire immunology drug candidate from Dren Bio for up to $1.9B.

**media[571513]**

PR NewswireBRIDGEWATER, N.J., March 14, 2025 BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza s

As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading...

**media[560956]**

**media[560955]**

Sanofi successfully prices EUR 1.5 billion of bond issue